Jessica Rehmel
Eli Lilly (United States)(US)
Publications by Year
Research Areas
Pharmacogenetics and Drug Metabolism, Drug Transport and Resistance Mechanisms, Analytical Chemistry and Chromatography, Computational Drug Discovery Methods, Diabetes Treatment and Management
Most-Cited Works
- → INTERACTIONS OF TWO MAJOR METABOLITES OF PRASUGREL, A THIENOPYRIDINE ANTIPLATELET AGENT, WITH THE CYTOCHROMES P450(2006)263 cited
- → Disposition and Metabolism of LY2452473, a Selective Androgen Receptor Modulator, in Humans(2012)40 cited
- → Physiologically‐Based Pharmacokinetic Modeling of Atorvastatin Incorporating Delayed Gastric Emptying and Acid‐to‐Lactone Conversion(2019)29 cited
- → Current Practices, Gap Analysis, and Proposed Workflows for PBPK Modeling of Cytochrome P450 Induction: An Industry Perspective(2021)28 cited
- → Abstract CT153: Pharmacokinetic drug interactions between abemaciclib and CYP3A inducers and inhibitors(2016)21 cited
- → Investigational Small-Molecule Drug Selectively Suppresses Constitutive CYP2B6 Activity at the Gene Transcription Level: Physiologically Based Pharmacokinetic Model Assessment of Clinical Drug Interaction Risk(2014)20 cited
- → Abemaciclib Does Not Have a Clinically Meaningful Effect on Pharmacokinetics of CYP1A2, CYP2C9, CYP2D6, and CYP3A4 Substrates in Patients with Cancer(2020)20 cited
- → CYP‐mediated drug–drug interactions with evacetrapib, an investigational CETP inhibitor: in vitro prediction and clinical outcome(2015)12 cited
- → Disposition and metabolism of LY2603618, a Chk-1 inhibitor following intravenous administration in patients with advanced and/or metastatic solid tumors(2014)11 cited
- → Disposition and metabolism of [ 14 C]-galunisertib, a TGF- β RI kinase/ALK5 inhibitor, following oral administration in healthy subjects and mechanistic prediction of the effect of itraconazole on galunisertib pharmacokinetics(2017)11 cited